ArticleBMC health services research2026

Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access.

Surasit Lochid-Amnuay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.